Heather Hamme
Family · Hanover, PANPI 1922572759
Payments from drug & device makers
Across 89 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$438
- Otsuka America Pharmaceutical, Inc.$366
- Novo Nordisk$205
- Amgen$126
- AstraZeneca$99
- Sumitomo Pharma America, Inc.$68
- plus $531 from 18 others
What the payments were for
- Food & beverage$1,834100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 23 | $438 |
| Otsuka America Pharmaceutical, Inc. | 14 | $366 |
| Novo Nordisk | 12 | $205 |
| Amgen | 2 | $126 |
| AstraZeneca | 6 | $99 |
| Sumitomo Pharma America, Inc. | 3 | $68 |
| Exact Sciences | 3 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $52 |
| Pfizer | 3 | $52 |
| Urovant Sciences Inc | 2 | $46 |
| AbbVie | 2 | $39 |
| GSK | 2 | $34 |
| Merck | 2 | $33 |
| Acadia Pharmaceuticals Inc | 2 | $32 |
| Astellas Pharma US Inc | 1 | $28 |
| Tactile Systems Technology Inc | 1 | $23 |
| Lilly USA, LLC | 1 | $20 |
| Bayer | 1 | $20 |
| Seqirus USA Inc | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$1,834 in reported general payments places this provider in the 80th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 198 | $146,337 |
| XareltoRivaroxaban | 52 | $30,678 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 49 | $14,447 |
| JardianceEmpagliflozin | 19 | $13,669 |
| CreonLipase/Protease/Amylase | 14 | $12,819 |
| VimpatLacosamide | 20 | $11,616 |
| JanuviaSitagliptin Phosphate | 11 | $11,242 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,183 |
| EntrestoSacubitril/Valsartan | 15 | $9,774 |
| MyrbetriqMirabegron | 11 | $9,656 |
| GemtesaVibegron | 15 | $9,193 |
| Spiriva HandihalerTiotropium Bromide | 13 | $7,084 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $5,358 |
| Formoterol Fumarate | 12 | $4,072 |
| Atorvastatin Calcium | 311 | $3,933 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $52 | $146,337198 claims |
| GSKArexvy, Trelegy Ellipta | $34 | $25,62963 claims |
| AbbVieCreon | $39 | $12,81914 claims |
| MerckJanuvia | $33 | $11,24211 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $9,65611 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $68 | $9,19315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,717 family providers in Pennsylvania.
Other family in Hanover
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.